Wealth Enhancement Trust Services’s Vanda Pharmaceuticals VNDA Stock Holding History

Wealth Enhancement Trust Services’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71K	Buy	+443	New	+$2.89K	﹤0.01%	954

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

LCML

Lionhunter Capital Management, LLC New York $222M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealth Enhancement Trust Services's VNDA Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 443 shares worth $2.71K. The stake represents ﹤0.01% of the portfolio and ranks #954 among its holdings.

104 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Wealth Enhancement Trust Services held 443 shares of Vanda Pharmaceuticals worth $2.71K as of Q2 2026.
Vanda Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #954 holding.
104 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.